Diferencia entre revisiones de «Clostridium difficile (peds)»

(Prepared the page for translation)
(Marked this version for translation)
 
Línea 1: Línea 1:
<languages/>
<languages/>
<translate>
<translate>
<!--T:1-->
''This page is for <u>pediatric</u> patients; for adult patients see [[Special:MyLanguage/clostridium difficile|clostridium difficile]].''
''This page is for <u>pediatric</u> patients; for adult patients see [[Special:MyLanguage/clostridium difficile|clostridium difficile]].''


==Background==
==Background== <!--T:2-->


<!--T:3-->
[[File:Pseudomembranous colitis 1.jpg|thumb|Pseudomembranous colitis with yellow pseudomembranes seen on the wall of the sigmoid colon.]]
[[File:Pseudomembranous colitis 1.jpg|thumb|Pseudomembranous colitis with yellow pseudomembranes seen on the wall of the sigmoid colon.]]
*[[Special:MyLanguage/Clostridium|Clostridium]] is a genus of [[Special:MyLanguage/Gram-positive bacteria|Gram-positive bacteria]]
*[[Special:MyLanguage/Clostridium|Clostridium]] is a genus of [[Special:MyLanguage/Gram-positive bacteria|Gram-positive bacteria]]
Línea 12: Línea 14:




===Pediatric Risk Factors===
===Pediatric Risk Factors=== <!--T:4-->


<!--T:5-->
*[[Special:MyLanguage/Antibiotic|Antibiotic]] exposure, particularly [[Special:MyLanguage/penicillins|penicillins]], [[Special:MyLanguage/cephalosporins|cephalosporins]], [[Special:MyLanguage/clindamycin|clindamycin]], [[Special:MyLanguage/fluoroquinolones|fluoroquinolones]]
*[[Special:MyLanguage/Antibiotic|Antibiotic]] exposure, particularly [[Special:MyLanguage/penicillins|penicillins]], [[Special:MyLanguage/cephalosporins|cephalosporins]], [[Special:MyLanguage/clindamycin|clindamycin]], [[Special:MyLanguage/fluoroquinolones|fluoroquinolones]]
*[[Special:MyLanguage/PPIs|PPIs]]
*[[Special:MyLanguage/PPIs|PPIs]]
Línea 20: Línea 23:




==Clinical Features==
==Clinical Features== <!--T:6-->


<!--T:7-->
''Varies according to severity and intrinsic host factors (immunosuppression, etc.).''
''Varies according to severity and intrinsic host factors (immunosuppression, etc.).''
*[[Special:MyLanguage/Diarrhea|Diarrhea]] that develops during antibiotic use or within 2 weeks of discontinuation
*[[Special:MyLanguage/Diarrhea|Diarrhea]] that develops during antibiotic use or within 2 weeks of discontinuation
Línea 32: Línea 36:




==Differential Diagnosis==
==Differential Diagnosis== <!--T:8-->


</translate>
</translate>
Línea 39: Línea 43:




==Evaluation==
==Evaluation== <!--T:9-->


<!--T:10-->
[[File:MPX1834 synpic40781.png|thumb|Pseudomembranous colitis from ''C. difficile'' on abdominal CT demonstratin diffuse colonic wall thickening and a shaggy endoluminal contour.]]
[[File:MPX1834 synpic40781.png|thumb|Pseudomembranous colitis from ''C. difficile'' on abdominal CT demonstratin diffuse colonic wall thickening and a shaggy endoluminal contour.]]
[[File:PMC5137169 gr1.png|thumb|Pseudomembranous colitis with (A) Accordion sign in transverse colon (thin arrows). (B) Colonic wall thickness, target sign (thick arrow), peritoneal fluid (thin arrow) and pericolonic fat stranding (arrowhead).]]
[[File:PMC5137169 gr1.png|thumb|Pseudomembranous colitis with (A) Accordion sign in transverse colon (thin arrows). (B) Colonic wall thickness, target sign (thick arrow), peritoneal fluid (thin arrow) and pericolonic fat stranding (arrowhead).]]


===Labs===
===Labs=== <!--T:11-->


<!--T:12-->
*C. diff toxin assay
*C. diff toxin assay
**Sn 63-94%, Sp 75-100%
**Sn 63-94%, Sp 75-100%
Línea 52: Línea 58:




===Testing Algorithm===
===Testing Algorithm=== <!--T:13-->


<!--T:14-->
''For patients with suspected Clostridium difficile associated diarrhea (CDAD)''
''For patients with suspected Clostridium difficile associated diarrhea (CDAD)''
*'''Low''' suspicion
*'''Low''' suspicion
Línea 65: Línea 72:




===Repeat testing===
===Repeat testing=== <!--T:15-->


<!--T:16-->
*Never a need for repeat testing within 7 days of a previous test
*Never a need for repeat testing within 7 days of a previous test
*NO NEED to repeat positive tests as symptoms resolve as a “test of cure”
*NO NEED to repeat positive tests as symptoms resolve as a “test of cure”
Línea 72: Línea 80:




===Pediatrics===
===Pediatrics=== <!--T:17-->


<!--T:18-->
*Testing in infants < 1 year of age not recommended due to high rates of colonization
*Testing in infants < 1 year of age not recommended due to high rates of colonization
**~40% of infants < 1 month are colonized and asymptomatic<ref>Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. Jangi S, Lamont JT. J Pediatr Gastroenterol Nutr. 2010 Jul; 51(1):2-7.</ref>
**~40% of infants < 1 month are colonized and asymptomatic<ref>Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. Jangi S, Lamont JT. J Pediatr Gastroenterol Nutr. 2010 Jul; 51(1):2-7.</ref>
Línea 80: Línea 89:




==Management==
==Management== <!--T:19-->


<!--T:20-->
*Stop offending antimicrobial agents, if possible
*Stop offending antimicrobial agents, if possible
*Initial occurrence and first recurrence of mild-moderate disease:<ref>D'Ostroph AR and So TY. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist. 2017; 10: 365–375.</ref>
*Initial occurrence and first recurrence of mild-moderate disease:<ref>D'Ostroph AR and So TY. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist. 2017; 10: 365–375.</ref>
Línea 97: Línea 107:




==Disposition==
==Disposition== <!--T:21-->


<!--T:22-->
*Admit:
*Admit:
**Severe [[Special:MyLanguage/diarrhea|diarrhea]]
**Severe [[Special:MyLanguage/diarrhea|diarrhea]]
Línea 105: Línea 116:




==[[Special:MyLanguage/Antibiotic Sensitivities|Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
==[[Special:MyLanguage/Antibiotic Sensitivities|Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== <!--T:23-->


<!--T:24-->
{| class="wikitable"
{| class="wikitable"
| align="center" style="background:#f0f0f0;"|'''Category'''
| align="center" style="background:#f0f0f0;"|'''Category'''
Línea 250: Línea 262:




==See Also==
==See Also== <!--T:25-->


<!--T:26-->
*[[Special:MyLanguage/Diarrhea|Diarrhea]]
*[[Special:MyLanguage/Diarrhea|Diarrhea]]
*[[Special:MyLanguage/Clostridium|Clostridium]]
*[[Special:MyLanguage/Clostridium|Clostridium]]




==References==
==References== <!--T:27-->


<!--T:28-->
<references/>
<references/>


<!--T:29-->
[[Category:ID]]
[[Category:ID]]
[[Category:GI]]
[[Category:GI]]
</translate>
</translate>

Revisión actual - 12:32 7 ene 2026

Otros idiomas:

This page is for pediatric patients; for adult patients see clostridium difficile.

Background

Pseudomembranous colitis with yellow pseudomembranes seen on the wall of the sigmoid colon.
  • Clostridium is a genus of Gram-positive bacteria
  • Most common cause of infectious diarrhea in hospitalized patients
  • Use contact isolation if suspect
  • Alcohol-based hand sanitizers do not reduce spores, but good hand washing does[1]


Pediatric Risk Factors


Clinical Features

Varies according to severity and intrinsic host factors (immunosuppression, etc.).

  • Diarrhea that develops during antibiotic use or within 2 weeks of discontinuation
  • Usually occurs after 7-10 days of antibiotics, as diarrhea before that time is more often poor tolerance to antibiotic
  • Recent discharge from hospital
  • Profuse watery diarrhea
  • Abdominal pain/tenderness
  • Fever
  • At the extreme, may present with sepsis secondary to intestinal perforation or toxic megacolon


Differential Diagnosis

Acute diarrhea

Infectious

Noninfectious

Watery Diarrhea

Traveler's Diarrhea


Evaluation

Pseudomembranous colitis from C. difficile on abdominal CT demonstratin diffuse colonic wall thickening and a shaggy endoluminal contour.
Pseudomembranous colitis with (A) Accordion sign in transverse colon (thin arrows). (B) Colonic wall thickness, target sign (thick arrow), peritoneal fluid (thin arrow) and pericolonic fat stranding (arrowhead).

Labs

  • C. diff toxin assay
    • Sn 63-94%, Sp 75-100%
  • Culture
    • Positive culture only means C. diff present, not necessarily that it is causing disease


Testing Algorithm

For patients with suspected Clostridium difficile associated diarrhea (CDAD)

  • Low suspicion
    • Send stool for C. diff toxin assay
      • Positive → treat (no further testing indicated)
      • Negative → do not treat (no further testing indicated)
  • High suspicion
    • Send stool for C. diff toxin assay AND treat empirically
      • Positive → treat (no further testing indicated)
      • Negative → Consider discussion with ID (false negative tests may occur); eval for other causes of diarrhea


Repeat testing

  • Never a need for repeat testing within 7 days of a previous test
  • NO NEED to repeat positive tests as symptoms resolve as a “test of cure”
  • NO NEED to repeat test soon after initial negative test (more likely to be a false positive test than a true positive test)


Pediatrics

  • Testing in infants < 1 year of age not recommended due to high rates of colonization
    • ~40% of infants < 1 month are colonized and asymptomatic[3]
    • ~15% in infants 6-12 months
    • By 2 years of age, normal flora is established, similar to adults[4]


Management

  • Stop offending antimicrobial agents, if possible
  • Initial occurrence and first recurrence of mild-moderate disease:[5]
  • Severe infection or second recurrence:
    • PO vancomycin 40 mg/kg/d in four divided doses, max 500 mg/day
    • If no improvement after 24-48 hours, oral vancomycin max dose may be increased to 2 g/d
    • Q6hr IV metronidazole, 30 mg/kg/d, may be added to intracolonic/enema vancomycin for ileus, inability to tolerate PO antibiotics
  • Multiple recurrences, other strategies, in consult with pediatric GI:
    • May benefit from tapering and pulse oral vancomycin over 1.5-2 months, as done in adults
    • Consider PO fidaxomicin in ≥ 6 year old patients at 200 mg twice daily for 10 dats


Disposition


Antibiotic Sensitivities[6]

Category Antibiotic Sensitivity
Penicillins Penicillin G X2
Penicillin V X1
Anti-Staphylocccal Penicillins Methicillin X1
Nafcillin/Oxacillin X1
Cloxacillin/Diclox. X1
Amino-Penicillins AMP/Amox X1
Amox-Clav X1
AMP-Sulb X2
Anti-Pseudomonal Penicillins Ticarcillin X1
Ticar-Clav X1
Pip-Tazo X1
Piperacillin X2
Carbapenems Doripenem X2
Ertapenem X2
Imipenem X2
Meropenem X2
Aztreonam R
Fluroquinolones Ciprofloxacin R
Ofloxacin X1
Pefloxacin X1
Levofloxacin R
Moxifloxacin R
Gemifloxacin X1
Gatifloxacin R
1st G Cephalo Cefazolin X1
2nd G. Cephalo Cefotetan X1
Cefoxitin R
Cefuroxime X1
3rd/4th G. Cephalo Cefotaxime R
Cefizoxime R
CefTRIAXone X1
Ceftaroline X1
CefTAZidime X1
Cefepime R
Oral 1st G. Cephalo Cefadroxil X1
Cephalexin X1
Oral 2nd G. Cephalo Cefaclor/Loracarbef X1
Cefproxil X1
Cefuroxime axetil X1
Oral 3rd G. Cephalo Cefixime X1
Ceftibuten X1
Cefpodox/Cefdinir/Cefditoren X1
Aminoglycosides Gentamicin R
Tobramycin R
Amikacin R
Chloramphenicol I
Clindamycin X1
Macrolides Erythromycin X1
Azithromycin X1
Clarithromycin X1
Ketolide Telithromycin X1
Tetracyclines Doxycycline X1
Minocycline X1
Glycylcycline Tigecycline X1
Daptomycin X1
Glyco/Lipoclycopeptides Vancomycin S
Teicoplanin S
Telavancin S
Fusidic Acid X1
Trimethoprim X1
TMP-SMX X1
Urinary Agents Nitrofurantoin X1
Fosfomycin X1
Other Rifampin X1
Metronidazole S
Quinupristin dalfoppristin I
Linezolid I
Colistimethate X1


See Also


References

  1. ↑ Leffler DA and Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015; 372:1539-1548.
  2. ↑ Marx et al. “Cholera and Gastroenteritis caused by Noncholera Vibrio Species”. Rosen’s Emergency Medicine 8th edition vol 1 pg 1245-1246.
  3. ↑ Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. Jangi S, Lamont JT. J Pediatr Gastroenterol Nutr. 2010 Jul; 51(1):2-7.
  4. ↑ Clostridium difficile Infection in children. Sammons JS, Toltzis P, Zaoutis TE. JAMA Pediatr. 2013 Jun; 167(6):567-73.
  5. ↑ D'Ostroph AR and So TY. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist. 2017; 10: 365–375.
  6. ↑ Sanford Guide to Antimicrobial Therapy 2014
Obtenido de «https://www.wikem.org/w/index.php?title=Clostridium_difficile_(peds)&oldid=380393»